| 6.96 -0.02 (-0.29%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.88 | 1-year : | 10.04 |
| Resists | First : | 7.6 | Second : | 8.6 |
| Pivot price | 6.78  |
|||
| Supports | First : | 6 | Second : | 4.99 |
| MAs | MA(5) : | 6.84  |
MA(20) : | 7.01 |
| MA(100) : | 6.74 |
MA(250) : | 5.99 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 48.6 |
D(3) : | 42.8 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 8.94 | Low : | 3.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PROF ] has closed below upper band by 39.5%. Bollinger Bands are 7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.1 - 7.14 | 7.14 - 7.17 |
| Low: | 6.77 - 6.81 | 6.81 - 6.85 |
| Close: | 6.89 - 6.96 | 6.96 - 7.02 |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Thu, 12 Feb 2026
Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease - Yahoo Finance
Thu, 12 Feb 2026
New prostate treatment earns Canadian tech its Mount Logan prize - Stock Titan
Thu, 12 Feb 2026
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow - Yahoo Finance
Wed, 11 Feb 2026
Profound Medical Honored with INOVAIT's 2025-2026 Mount Logan Award Recognizing the TULSA Procedure for Prostate Disease - Bitget
Thu, 05 Feb 2026
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health - Yahoo Finance
Thu, 05 Feb 2026
Profound Medical Corp Celebrates 500th Sonalleve® Procedure at PRO FAMILIA - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 36 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 34.3 (%) |
| Shares Short | 1,130 (K) |
| Shares Short P.Month | 1,130 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.07 |
| Profit Margin | -275.2 % |
| Operating Margin | -168.6 % |
| Return on Assets (ttm) | -62.5 % |
| Return on Equity (ttm) | -124.5 % |
| Qtrly Rev. Growth | 86.8 % |
| Gross Profit (p.s.) | 0.28 |
| Sales Per Share | 0.39 |
| EBITDA (p.s.) | -1.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -5.28 |
| PEG Ratio | 0 |
| Price to Book value | 6.5 |
| Price to Sales | 17.66 |
| Price to Cash Flow | -6.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|